Cellectar Advances TNBC Treatment with First Patient in CLR 125 Phase 1b Trial — Cellectar Biosciences, Inc.

Event summary

First patient enrolled in Phase 1b trial of CLR 125 for refractory triple-negative breast cancer (TNBC).
CLR 125 is an Auger-emitting radioconjugate designed for intracellular DNA damage in tumor cells.
Study will evaluate three dose levels across approximately 45 patients with relapsed/refractory TNBC.
Additional study sites to be activated in Q2 2026, with safety and efficacy updates expected throughout the year.

The big picture

Cellectar's Phase 1b trial for CLR 125 targets a critical gap in TNBC treatment, where aggressive subtypes lack targeted therapies. The study builds on the company’s Phospholipid Drug Conjugate (PDC) platform, which has already secured multiple regulatory designations for its lead candidate, iopofosine I 131. Success here could position Cellectar as a key player in precision oncology, particularly if CLR 125 demonstrates differentiated safety and efficacy profiles.

What we're watching

Clinical Validation: Whether CLR 125 demonstrates sufficient tumor selectivity and efficacy to differentiate itself in the TNBC space.
Regulatory Pathway: The pace at which Cellectar can advance CLR 125 through subsequent trial phases given its proprietary PDC platform's prior regulatory designations.
Competitive Positioning: How Cellectar leverages the success of iopofosine I 131 to bolster investor confidence in its broader radioconjugate pipeline.